Generex Biotechnology Corporation (GNBT)

Oncology Corporate Profile

Stock Performance

3.6500
0.1500

HQ Location

33 Harbour Square, Suite 202
Toronto, Ontario, Canada M5J 2G2,

Company Description

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The company's liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using our proprietary RapidMist™ device.

Website: http://www.generex.com/

This company does not have any commercial products

This company does not have any pipeline products

Source: http://www.generex.com

Recent News Headlines

Non-Physician Practitioners Playing Larger Roles in Cancer Care

8/25/2015 11:04 am

(CureToday.com) Aug 20, 2015 - In the face of a shortage of oncologists, non-physician practitioners are playing larger roles on cancer-care teams.

The Cost Of Emerging Drugs: Quebec's Wrenching Choices

8/25/2015 11:04 am

(Montreal Gazette) Aug 22, 2015 - No one could blame Noëlla Panneton for accusing the Quebec government of playing God. When she learned she had pancreatic cancer three years ago, she was denied coverage for a potentially life-saving chemotherapy treatment because at age 74, she wasn’t considered a good investment.

Google Reveals Gigantic Ambitions To Fight Cancer, Diabetes, Parkinson's, Heart Problems

8/25/2015 11:03 am

(Forbes) Aug 24, 2015 - Google is pumping vast amounts of cash into its cutting-edge life sciences plans, turning a secretive unit based on smart contact lenses into a high powered, expert company.

Kyle Bass’s Challenge to Two Acorda Drug Patents Rejected

8/25/2015 11:03 am

(Bloomberg) Aug 24, 2015 - Kyle Bass has lost the first round in his battle with the drug industry.

Rhode Island Move To Mandate HPV Vaccine In Schools Faces Criticism

8/25/2015 11:02 am

(FoxNews.com/Reuters) Aug 25, 2015 - When Rhode Island seventh graders start school next month, the state's Department of Health will require they be vaccinated against the sexually transmitted human papillomavirus, over the protests of parent groups.

Children With Cancer Go Without Chemo For Weeks In Venezuela Due To Medicine Shortage

8/25/2015 11:02 am

(Fox News Latino) Aug 24, 2015 - According to Freddy Ceballos, president of Venezuela’s Pharmaceutical Federation, it isn’t just cancer medication that is in short supply. Ceballos said there is a shortage on 70 percent of all medications.

Eben Rosenthal, MD, Named Medical Director of the Stanford Cancer Center

8/25/2015 11:02 am

(Stanford Health Care) Aug 24, 2015 - Stanford Health Care today announced that Eben L. Rosenthal, MD, was recently named the new Medical Director of the Stanford Cancer Center and associate director of clinical care of the Stanford Cancer Institute.

Rathmell to Lead New Center for Immunobiology

8/25/2015 11:02 am

(VUMC Reporter) Aug 20, 2015 - Jeffrey Rathmell, Ph.D., has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology and Immunology, the Department of Medicine and Vanderbilt-Ingram Cancer Center (VICC).

Amgen Files for U.S. Approval of Therapy for Dialysis Patients

8/25/2015 11:02 am

(NASDAQ/Dow Jones Business News) Aug 25, 2015 - Amgen submitted a new drug application to the FDA for its intravenous treatment for secondary hyperparathyroidism in patients with chronic kidney disease.

Report: Nearly 47 Million People Now Have Dementia

8/25/2015 11:02 am

(New York Times/Associated Press) Aug 25, 2015 - Health researchers say there are now nearly 47 million people living with dementia globally, up from 35 million in 2009. They warned that without a medical breakthrough, numbers will likely double every 20 years.

FDA Grants Orphan Drug Designation for Tocagen's Toca 511 & Toca FC, an Investigational Immuno-Oncology Treatment for Glioblastoma

8/25/2015 11:01 am

(KCEN-TV/NBC [Temple, TX]) Aug 25, 2015 - Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.

Experts Call For Equal Access To CML Therapies In The UK

8/25/2015 11:01 am

(PharmaTimes [UK]) Aug 25, 2015 - Medical experts are slamming a decision by NHS cost regulators that restricts use of Ariad’s Iclusig in the treatment of chronic myeloid leukaemia in England while patients in Scotland and Wales get full access to the novel drug.

MorphoSys, immatics Launch Immuno-Oncology Alliance

8/25/2015 11:01 am

(Genetic Engineering & Biotechnology News) Aug 25, 2015 - MorphoSys said today it will partner with immatics biotechnologies to develop new antibody-based immune-oncology treatments to fight multiple cancer antigens recognized by T cells. The value of the strategic alliance was not disclosed.

Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology

8/25/2015 11:01 am

(Benzinga) Aug 24, 2015 - Burning Rock and Illumina, Inc. today announced they have entered into an agreement whereby Burning Rock will develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.

Relapse, Poor Survival in Acute Leukemia Linked to Genetic Mutations that Persist in Remission

8/25/2015 11:00 am

(WUSTL) Aug 25, 2015 - For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.

Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment

5/15/2015 12:19 pm

(Morningstar Advisor) May 14, 2015 - Generex Biotechnology Corporation announced today that updated data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO).

Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial

1/13/2014 11:51 am

(Yahoo! Finance) Jan 13, 2014 - Generex Biotechnology Corporation today announced completion of enrollment of the Antigen Express, Inc. AE37 breast cancer immunotherapy trial.

Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial

1/13/2014 11:05 am

(Yahoo! Finance) Jan 13, 2014 - Generex Biotechnology Corporation today announced completion of enrollment of the Antigen Express, Inc. AE37 breast cancer immunotherapy trial.

Novartis in Regenerex Stem Cell Deal to Ease Kidney Transplants

9/6/2013 11:35 am

(Bloomberg) Sep 6, 2013 - Novartis AG entered a collaboration with Regenerex LLC, gaining access to stem cell technology that may help kidney transplant patients avoid taking anti-rejection medicine for life.

Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine

6/7/2012 11:41 am

(MarketWatch) June 7, 2012 - Generex Biotechnology Corporation announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc.

Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine

6/7/2012 11:04 am

(MarketWatch) June 7, 2012 - Generex Biotechnology Corporation announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc.

Generex Announces Presentation of New Immune Response Data From AE37 Phase II Breast Cancer Trial at ASCO 2012

6/5/2012 03:17 pm

(Yahoo! Finance) June 5, 2012 - Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) on June 2, 2012 in Chicago, IL.

Generex Announces Presentation of New Immune Response Data From AE37 Phase II Breast Cancer Trial at ASCO 2012

6/5/2012 03:01 pm

(Yahoo! Finance) June 5, 2012 - Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) on June 2, 2012 in Chicago, IL.

Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS

12/8/2011 03:02 pm

(Generex) Dec 8, 2011 - Generex Biotechnology Corporation today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

Biotech Stock Mailbag: Generex Bio

6/24/2011 10:43 am

(TheStreet) June 24, 2011 - Adam Feuerstein comments on the surge in Oncothyreon's stock price and the company's experimental cancer immunotherapy Stimuvax, the upcoming FDA September 1 decision date for Adventrx's Exelbine; also, Spectrum Pharmaceuticals and Northwest Biotherapeutics.

Biotech Stock Mailbag: Generex Bio

6/24/2011 10:43 am

(TheStreet) June 24, 2011 - Adam Feuerstein comments on the surge in Oncothyreon's stock price and the company's experimental cancer immunotherapy Stimuvax, the upcoming FDA September 1 decision date for Adventrx's Exelbine; also, Spectrum Pharmaceuticals and Northwest Biotherapeutics.

Biotech Stock Mailbag: Generex Bio

6/24/2011 10:43 am

(TheStreet) June 24, 2011 - Adam Feuerstein comments on the surge in Oncothyreon's stock price and the company's experimental cancer immunotherapy Stimuvax, the upcoming FDA September 1 decision date for Adventrx's Exelbine; also, Spectrum Pharmaceuticals and Northwest Biotherapeutics.

Public Companies Embrace Investors Online at May 5th RetailInvestorConferences.com Event

5/2/2011 09:03 pm

[PR Newswire] - BetterInvesting , PR Newswire and MUNCmedia today announced the agenda of the May 5th RetailInvestorConferences.com, the monthly online investor conference series. Individual investors, institutional investors and analysts are invited.

Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas

3/25/2011 12:02 pm

(Bellicum) Mar 25, 2011 - The award will fund personnel, manufacturing, and clinical testing of Bellicum's CaspaCIDe™ therapy, which promises to substantially improve outcomes for late stage cancer patients.

Gilead HIV Drug as Effective as Merck Drug in Trial

3/23/2011 12:05 pm

(Reuters) Mar 23, 2011 - Gilead Sciences Inc. said on Wednesday that its experimental HIV drug elvitegravir proved as effective as a drug made by Merck & Co in a late-stage clinical trial.

Lilly’s Neuroscience Research Chief Resigns

2/25/2011 12:00 am

(WSJ Health Blog) Feb 24, 2011 - The head of Eli Lilly’s research into Alzheimer’s disease, schizophrenia and other neurological diseases is unexpectedly leaving the company.

Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study

1/25/2011 12:00 am

(MSN Money) Jan 25, 2011 - Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., announced today that it has amended the Clinical Study Agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. in regard to the on-going Phase II clinical study of Antigen's AE37 novel immunotherapeutic vaccine for the treatment of breast cancer.

Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines

1/6/2011 12:00 am

(TradingMarkets) Jan 6, 2011 - Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc., and RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, today announced that they have obtained positive early research data from their collaboration to explore the use of RXi's RNAi technology to develop proprietary vaccine formulations for active immunotherapy.

Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data

12/6/2010 12:00 am

(Yahoo! Finance) Dec 6, 2010 - Generex Biotechnology Corporation today announced two presentations of data obtained from its on-going Phase II trial of its novel immunotherapeutic AE37 vaccine in breast cancer patients.

Generex Provides Additional Details for October 21st Live Video Webcast

10/20/2010 01:00 pm

[PR Newswire] - Generex Biotechnology Corporation today announced additional details for its live video webcast scheduled for tomorrow, Thursday, October 21, 2010, in New York City.